Results of the COMPARE Study After 2 Years: Low Dose vs. High Dose Paclitaxel-Coated Balloons

The development of new devices and techniques has expanded the range of patients who benefit from endovascular treatment of femoropopliteal lesions. Paclitaxel-eluting devices have improved clinical results and treated-vessel patency at follow-up compared with conventional angioplasty. Currently, devices with different doses of paclitaxel are available in the market.

Resultados del estudio COMPARE a 2 años: Balones cubiertos de Paclitaxel con bajas dosis vs altas dosis

The COMPARE (Compare I Pilot Study for the Treatment of Subjects with Symptomatic Femoropopliteal Artery Disease) study compared low-dose (Ranger) vs. high-dose (IN-PACT) paclitaxel-coated balloons, showing that the former were non-inferior in terms of efficacy and safety after 1 year.

The aim of this prospective, multicenter study was to evaluate efficacy and safety results after 2 years.

The primary endpoint was absence of clinically guided treated-vessel revascularization or restenosis assessed by a Doppler study. Additionally, researchers analyzed a safety endpoint and clinical results.

This study analyzed 414 patients randomized between the low-dose arm and the high-dose arm. Mean patient age was 68 years old, and most subjects were male. The most frequent clinical presentation was Rutherford class III. There were no differences between groups in terms of the characteristics of treated lesions (lesion length, chronic occlusion %, and calcification level). Technical and procedural success rates were also similar.

Read also: Prognostic Impact of Acute Kidney Injury Following Tricuspid Transcatheter Edge-to-Edge Repair.

After 2 years, the patency rate was 70% for the low-dose arm, and 71% for the high-dose arm (p = 0.96). There was no difference in all-cause mortality or clinically guided revascularization.

Conclusion

This study has shown a sustained and comparable effect regarding the treatment of femoropopliteal lesions between balloons coated with low and high doses of paclitaxel in terms of treated-vessel patency and need for revascularization after 2 years.

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: Low-Dose vs High-Dose Paclitaxel-Coated Balloons for Femoropopliteal Lesions 2-Year Results From the COMPARE Trial.

Reference: Sabine Steiner, MD et al J Am Coll Cardiol Intv 2022.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

TCT 2024 | PEERLESS: Mechanical Thrombectomy with FlowTriever vs Catheter-Directed Thrombolysis in Intermediate Risk PTE

Pulmonary embolism (PE) continues to be the third cause of cardiovascular mortality. The current clinical guidelines recommend anticoagulation in intermediate risk patients presenting right...

Atherosclerotic Renal Artery Stenosis: To Revascularize or Not

At long term, atherosclerotic renal artery stenosis (RAS) can lead to hypertension, chronic kidney disease, and cardiac failure. Historically, these patients have been referred...

Endovascular Management of Chronic TEPH: Is Coronary Management Extrapolatable in This Scenario?

Chronic thromboembolic pulmonary hypertension (CTEPH) is a condition that causes significant functional limitation. Its surgical treatment, known as pulmonary endarterectomy (PEA), has improved the...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...